NASDAQ:APLS

Apellis Pharmaceuticals Stock Forecast, Price & News

$45.01

-1.19 (-2.58 %)

(As of 02/25/2021 10:09 AM ET)

Add

Compare

Today's Range

$45.01

Now: $45.01▼

$46.14

50-Day Range

$42.64

MA: $48.58▼

$57.39

52-Week Range

$16.85

Now: $45.01▼

$58.47

Volume3,044 shs

Average Volume628,796 shs

Market Capitalization$3.41 billion

P/E RatioN/A

Dividend YieldN/A

Beta1.47

Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin disease, C3 glomerulopathy, IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company is also developing APL-9, which is in single ascending dose Phase I randomized, double-blind, and placebo-controlled clinical trials for the prevention of immune system activation coincident with adeno-associated virus for intravenous administration. Apellis Pharmaceuticals, Inc. has a strategic collaboration with Swedish Orphan Biovitrum AB (publ) for the advancement of pegcetacoplan, a C3 therapy for the treatment of multiple rare diseases, including paroxysmal nocturnal hemoglobinuria. The company was founded in 2009 and is based in Waltham, Massachusetts.

Headlines

Apellis Announces Agreements to Exchange Approximately $107.5 Million in Principal Amount of Its 3.500% Convertible Senior Notes Due 2026 for Common Stock
January 7, 2021 | finance.yahoo.com

First Week of APLS February 2021 Options Trading
December 18, 2020 | nasdaq.com

Apellis remains a top pick at Baird after AstraZeneca/Alexion deal
December 16, 2020 | seekingalpha.com

J&J (JNJ) Acquires Rights for Hemera Biosciences' Gene Therapy
December 3, 2020 | msn.com

Apellis Pharmaceuticals to Present at the 2020 Evercore ISI HealthCONx Conference
November 30, 2020 | finance.yahoo.com

FDA accepts Apellis' pegcetacoplan application for a rare blood disorder
November 16, 2020 | seekingalpha.com

Apellis Announces FDA Acceptance and Priority Review of the New Drug Application for Pegcetacoplan for the Treatment of PNH
November 16, 2020 | finance.yahoo.com

Apellis Announces Late-Breaking Presentation of Largest Retrospective Database Study in Geographic Atrophy (GA) at AAO 2020 Virtual
November 13, 2020 | finance.yahoo.com

Apellis Pharmaceuticals Reports Third Quarter 2020 Financial Results
November 2, 2020 | finance.yahoo.com

Apellis Pharmaceuticals (APLS) & Sobi Collaboration for Systemic Pegcetacoplan - Slideshow
October 30, 2020 | seekingalpha.com

Apellis Pharmaceuticals (APLS) COVID-19 Study Updates - Slideshow
October 30, 2020 | seekingalpha.com

Biopharma startups sign drug licensing deals worth $2.5B
October 27, 2020 | bizjournals.com

See More Headlines

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:APLS

Previous Symbol

CUSIPN/A

CIK1492422

Webwww.apellis.com

Phone617-977-5700

Employees350

Year FoundedN/A

Debt

Debt-to-Equity Ratio3.34

Current Ratio9.86

Quick Ratio9.86

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual SalesN/A

Price / SalesN/A

Cash FlowN/A

Price / Cash FlowN/A

Book Value$0.46 per share

Price / Book97.85

Profitability

EPS (Most Recent Fiscal Year)($4.64)

Net Income$-304,710,000.00

Net MarginsN/A

Return on Equity-336.93%

Return on Assets-78.28%

Miscellaneous

Outstanding Shares75,737,000

Market Cap$3.41 billion

Next Earnings Date2/25/2021 (Confirmed)

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

1.75 out of 5 stars

Medical Sector

167th out of 1,958 stocks

Pharmaceutical Preparations Industry

74th out of 772 stocks

4.4 Analyst's Opinion

Consensus Rating
Apellis Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 2.80, and is based on 10 buy ratings, 4 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $117.64, Apellis Pharmaceuticals has a forecasted upside of 161.4% from its current price of $45.01.
Amount of Analyst Coverage
Apellis Pharmaceuticals has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.

2.7 Community Rank

Outperform Votes
Apellis Pharmaceuticals has received 223 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Apellis Pharmaceuticals has received 188 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Apellis Pharmaceuticals has received 54.26% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Apellis Pharmaceuticals and other stocks. Vote “Outperform” if you believe APLS will outperform the S&P 500 over the long term. Vote “Underperform” if you believe APLS will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Apellis Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Apellis Pharmaceuticals does not have a long track record of dividend growth.

1.7 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Apellis Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $5,519,441.00 in company stock.
Percentage Held by Insiders
Only 9.50% of the stock of Apellis Pharmaceuticals is held by insiders.
Percentage Held by Institutions
81.20% of the stock of Apellis Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Apellis Pharmaceuticals are expected to decrease in the coming year, from ($5.96) to ($6.50) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Apellis Pharmaceuticals is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Apellis Pharmaceuticals is -6.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Apellis Pharmaceuticals has a P/B Ratio of 97.85. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

$45.01

-1.19 (-2.58 %)

(As of 02/25/2021 10:09 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive APLS News and Ratings via Email

Sign-up to receive the latest news and ratings for APLS and its competitors with MarketBeat's FREE daily newsletter.

Apellis Pharmaceuticals (NASDAQ:APLS) Frequently Asked Questions

Is Apellis Pharmaceuticals a buy right now?

15 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Apellis Pharmaceuticals in the last twelve months. There are currently 4 hold ratings, 10 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" Apellis Pharmaceuticals stock.
View analyst ratings for Apellis Pharmaceuticals or view top-rated stocks.

What stocks does MarketBeat like better than Apellis Pharmaceuticals?

Wall Street analysts have given Apellis Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Apellis Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Apellis Pharmaceuticals' next earnings date?

Apellis Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, February 25th 2021.
View our earnings forecast for Apellis Pharmaceuticals.

How were Apellis Pharmaceuticals' earnings last quarter?

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) posted its earnings results on Saturday, November, 7th. The company reported ($1.79) EPS for the quarter, missing the Zacks' consensus estimate of ($1.58) by $0.21. The company had revenue of $0.65 million for the quarter.
View Apellis Pharmaceuticals' earnings history.

How has Apellis Pharmaceuticals' stock been impacted by COVID-19?

Apellis Pharmaceuticals' stock was trading at $27.23 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, APLS shares have increased by 65.3% and is now trading at $45.01.
View which stocks have been most impacted by COVID-19.

What price target have analysts set for APLS?

15 Wall Street analysts have issued 12-month price objectives for Apellis Pharmaceuticals' stock. Their forecasts range from $29.00 to $875.00. On average, they anticipate Apellis Pharmaceuticals' stock price to reach $117.64 in the next year. This suggests a possible upside of 161.4% from the stock's current price.
View analysts' price targets for Apellis Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Apellis Pharmaceuticals' key executives?

Apellis Pharmaceuticals' management team includes the following people:

Dr. Cedric Francois, Co-Founder, Pres, CEO & Director (Age 49, Pay $987.91k)
Dr. Pascal Deschatelets, Co-Founder & Chief Scientific Officer (Age 51, Pay $712.58k)
Mr. Alec Machiels J.D., MBA, Co-Founder & Independent Director (Age 48, Pay $61.75k)
Mr. Timothy E. Sullivan, Chief Financial Officer (Age 50, Pay $610.65k)
Dr. Federico Grossi M.D., Ph.D., Co-Founder & Chief Medical Officer (Age 47)
Ms. Nur Nicholson, Chief Technical Operations Officer
Mr. David O. Watson, Gen. Counsel (Age 48)
Ms. Karen Lewis, Chief People Officer
Dr. Lukas Scheibler M.D., Ph.D., Chief Innovation Officer (Age 50)
Mr. Adam J. Townsend, Chief Commercial Officer (Age 44)

What is Cedric Francois' approval rating as Apellis Pharmaceuticals' CEO?

6 employees have rated Apellis Pharmaceuticals CEO Cedric Francois on Glassdoor.com. Cedric Francois has an approval rating of 100% among Apellis Pharmaceuticals' employees. This puts Cedric Francois in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Apellis Pharmaceuticals' key competitors?

Some companies that are related to Apellis Pharmaceuticals include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Grifols (GRFS), Mirati Therapeutics (MRTX), Dr. Reddy's Laboratories (RDY), BridgeBio Pharma (BBIO), Jazz Pharmaceuticals (JAZZ), Ultragenyx Pharmaceutical (RARE), Zai Lab (ZLAB), Arrowhead Pharmaceuticals (ARWR), Ascendis Pharma A/S (ASND), Ionis Pharmaceuticals (IONS), ACADIA Pharmaceuticals (ACAD), United Therapeutics (UTHR) and Schrödinger (SDGR).
View all of APLS's competitors.

What other stocks do shareholders of Apellis Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Apellis Pharmaceuticals investors own include AbbVie (ABBV), OPKO Health (OPK), Fate Therapeutics (FATE), Sorrento Therapeutics (SRNE), Viking Therapeutics (VKTX), Allena Pharmaceuticals (ALNA), Amarin (AMRN), Anavex Life Sciences (AVXL), Axsome Therapeutics (AXSM) and BioXcel Therapeutics (BTAI).

When did Apellis Pharmaceuticals IPO?

(APLS) raised $150 million in an initial public offering on Thursday, November 9th 2017. The company issued 10,700,000 shares at $13.00-$15.00 per share. Citigroup, J.P. Morgan and Evercore ISI served as the underwriters for the IPO.

What is Apellis Pharmaceuticals' stock symbol?

Apellis Pharmaceuticals trades on the NASDAQ under the ticker symbol "APLS."

Who are Apellis Pharmaceuticals' major shareholders?

Apellis Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (7.94%), Price T Rowe Associates Inc. MD (4.02%), Jennison Associates LLC (3.66%), Victory Capital Management Inc. (2.52%), Avidity Partners Management LP (1.02%) and Northern Trust Corp (0.91%). Company insiders that own Apellis Pharmaceuticals stock include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Morningside Venture Investment, Nicole D Perry, Pascal Deschatelets, Timothy Eugene Sullivan and Victoria L Brown.
View institutional ownership trends for Apellis Pharmaceuticals.

Which major investors are selling Apellis Pharmaceuticals stock?

APLS stock was sold by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Victory Capital Management Inc., Clough Capital Partners L P, Barclays PLC, Jennison Associates LLC, Russell Investments Group Ltd., State of New Jersey Common Pension Fund D, and Northern Trust Corp. Company insiders that have sold Apellis Pharmaceuticals company stock in the last year include A Sinclair Dunlop, Alec Machiels, Cedric Francois, David O Watson, Federico Grossi, Nicole D Perry, and Victoria L Brown.
View insider buying and selling activity for Apellis Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Apellis Pharmaceuticals stock?

APLS stock was bought by a variety of institutional investors in the last quarter, including Ghost Tree Capital LLC, Renaissance Technologies LLC, FIL Ltd, Avidity Partners Management LP, Lisanti Capital Growth LLC, Tri Locum Partners LP, Federated Hermes Inc., and Price T Rowe Associates Inc. MD. Company insiders that have bought Apellis Pharmaceuticals stock in the last two years include Morningside Venture Investment, and Timothy Eugene Sullivan.
View insider buying and selling activity for Apellis Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Apellis Pharmaceuticals?

Shares of APLS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Apellis Pharmaceuticals' stock price today?

One share of APLS stock can currently be purchased for approximately $45.01.

How much money does Apellis Pharmaceuticals make?

Apellis Pharmaceuticals has a market capitalization of $3.41 billion. The company earns $-304,710,000.00 in net income (profit) each year or ($4.64) on an earnings per share basis.

How many employees does Apellis Pharmaceuticals have?

Apellis Pharmaceuticals employs 350 workers across the globe.

What is Apellis Pharmaceuticals' official website?

The official website for Apellis Pharmaceuticals is www.apellis.com.

Where are Apellis Pharmaceuticals' headquarters?

Apellis Pharmaceuticals is headquartered at 100 FIFTH AVENUE, WALTHAM MA, 02451.

How can I contact Apellis Pharmaceuticals?

Apellis Pharmaceuticals' mailing address is 100 FIFTH AVENUE, WALTHAM MA, 02451. The company can be reached via phone at 617-977-5700 or via email at [email protected]

This page was last updated on 2/25/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here